Move will add to RTI Health Solutions’ integrated safety capabilities
Research Triangle Park, NC – In a move that will strengthen the capabilities of RTI Health Solutions, RTI International today announced the acquisition of Cary-based pharmaceutical safety surveillance and consulting company Integrated Safety Systems, Inc (ISS).
The addition will add depth to RTI Health Solutions’ existing integrated safety expertise and bring new pharmacovigilance capabilities to its portfolio of services.
Pharmacovigilance is the process of monitoring the safety of medicines, an activity that is essential for evaluation of the risk-benefit relationship of drugs.
“This acquisition enhances our ability to provide a total and integrated safety solution to our clients,” said Allen Mangel, vice president of RTI Health Solutions.
As a result of the acquisition, effective today, all six former ISS staff members will join the RTI Health Solutions group.
“We are very pleased to add these talented researchers to our RTI family,” said RTI President Victoria Haynes. “Their addition will strengthen RTI Health Solutions’ very successful risk management capabilities.”
“We are excited to have the opportunity to join RTI Health Solutions,” said Dr. Michael KIepper, president and founder of ISS. “This is a team that shares our values and goal of helping our clients provide safe and effective medicines to patients.”
The staff members will remain in their Cary offices until May when they will move into RTI Health Solutions’ offices at 200 Park in the Research Triangle Park.
Formed in 2000, RTI Health Solutions (www.rtihs.org) is a business unit of RTI International, focusing on services to the pharmaceutical, biotechnology and medical device industry. RTI Health Solutions has more than 90 employees in the United States and Europe including experts in epidemiology, biostatistics, health economics, psychometrics, reimbursement strategy, medical writing and clinical development.
The group combines its consulting and research expertise to assess drug safety, conduct epidemiologic studies, design and evaluate risk management programs, evaluate economic and clinical impacts of treatment, develop reimbursement dossiers, and implement patient-reported outcomes and health-related quality of life studies.
Learn more about our pharmacovigilance and drug safety services: pharmacovigilance and drug safety services